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Abstract
Activation of hepatic stellate cells (HSCs) plays an important role in the development of cirrhosis through the increased
production of collagen and the enhanced contractile response to vasoactive mediators such as endothelin-1 (ET-1). The
farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that is highly expressed in liver, kidneys,
adrenals, and intestine. FXR is also expressed in HSCs and activation of FXR in HSCs is associated with significant decreases
in collagen production. However, little is known about the roles of FXR in the regulation of contraction of HSCs. We report in
this study that treatment of quiescent HSCs with GW4064, a synthetic FXR agonist, significantly inhibited the HSC
transdifferentiation, which was associated with an inhibition of the upregulation of ET-1 expression. These GW4064-treated
cells also showed reduced contractile response to ET-1 in comparison to HSCs without GW4064 treatment. We have further
shown that GW4064 treatment inhibited the ET-1-mediated contraction in fully activated HSCs. To elucidate the potential
mechanism we showed that GW4064 inhibited ET-1-mediated activation of Rho/ROCK pathway in activated HSCs. Our
studies unveiled a new mechanism that might contribute to the anti-cirrhotic effects of FXR ligands.
Citation: Li J, Kuruba R, Wilson A, Gao X, Zhang Y, et al. (2010) Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand. PLoS
ONE 5(11): e13955. doi:10.1371/journal.pone.0013955
Editor: Frank Beier, University of Western Ontario, Canada
Received May 3, 2010; Accepted October 22, 2010; Published November 11, 2010
Copyright:  2010 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by the National Institutes of Health [Grant HL091828] (to S.L.). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sol4@pitt.edu
Introduction
Hepatic fibrosis or cirrhosis is a chronic scarring process of the
liver that is associated with increased and altered deposition of
extracellular matrix (ECM). During the chronic liver injury,
hepatic stellate cells (HSCs) undergo a process of transdifferentia-
tion from a resting, fat-storing phenotype to a myofibroblast-like
phenotype characterized by expression of fibroblastic cell markers
such as a-smooth muscle actin (a-SMA). Activated HSCs produce
increased amounts of ECM components that contribute signifi-
cantly to the fibrotic changes in cirrhosis [1,2]. In addition,
activated HSCs gain contractile phenotype and increasing
evidence suggests that the contractile force generated by HSCs
contributes to the regulation of sinusoidal blood flow and the
development of portal hypertension [3]. A number of vasoactive
molecules can trigger contractile response in HSCs with
endothelin-1 being the most potent constrictor [4,5,6]. The
regulation of HSC activation during the chronic liver injury is
not completely understood, however, a number of studies have
suggested that members of the nuclear receptor (NR) superfamily
negatively regulate HSC transdifferentiation [7,8,9].
The farnesoid X receptor (FXR) belongs to the superfamily of
ligand-activated transcriptional factors. FXR has the typical nuclear
receptor structure and can be activated by structurally different
ligands, including several primary and secondary bile acid (BA)
species conjugated to either taurine or glycine [10]. In addition to
BAs, a number of synthetic FXR agonists have been developed,
among which GW4064 is one of the most potent FXR agonists
[11,12]. FXR is highly expressed in liver, kidney, adrenals, and
intestine and plays a key role in the homeostasis of cholesterol and
BAs via regulation of the expression of the genes that are involved in
the synthesis and transport of BAs [13,14,15]. FXR is also expressed
in HSCs and activation of FXR has been shown to negatively
regulate HSC transdifferentiation, which is associated with a
significant inhibition of both basal and TGF-b-induced collagen
production [16]. Treatment with a FXR ligand significantly inhibited
the activation of HSCs and a concomitant decrease in collagen
deposition in a rat model of CCl4-induced liver injury [17]. However,
little is known about the roles of FXR in the regulation of contraction
of HSCs. We report in this study that treatment of quiescent HSCs
with GW4064, a synthetic FXR agonist, significantly inhibited the
HSC transdifferentiation, which was associated with an inhibition of
the upregulation of ET-1 expression. These GW4064-treated cells
also showed reduced contractile response to ET-1 in comparison to
untreated HSCs. We have further shown that GW4064 treatment
inhibited the ET-1-mediated contraction in fully activated HSCs.
Our studies unveiled a new mechanism that might contribute to the
anti-cirrhotic effects of FXR ligands.
Results
GW4064 treatment inhibited transdifferentiation of HSCs
Freshly isolated rat HSCs transdifferentiated to a myofibro-
blastic phenotype in vitro when cultured on plastic in serum-
containing media, as evidenced by an induction of a-SMA at
mRNA (Fig. 1A) and protein level (Fig. 1B). This activation
process was significantly inhibited when the cells were continu-
ously treated with GW4064. Our results were in agreement with
those by Fiorucci and colleagues with different FXR ligands [17].
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GW4064 treatment inhibited the upregulation of ET-1
expression during HSC activation
It has been shown that ET-1 expression is significantly
upregulated during HSC transdifferentiation. A similar result
was shown in our study with rat HSCs as examined by real-time
RT-PCR (Fig. 2A). This upregulation was significantly inhibited
when HSCs were continuously treated with GW4064.
Fig. 2B also shows that transdifferentiation of HSCs was
associated with upregulation of ETB receptor. This is in agreement
with the study by Chi and colleagues [18]. However, GW4064
treatment had no effects on changes of ETB expression during the
activation of HSCs. GW4064 had no effect either on the expression
levels of ETA during the transdifferentiation (Fig. 2C).
GW6064 treatment of HSCs led to reduced contractile
response to ET-1
Following the demonstration that GW4064 treatment inhibited
the transdifferentiation of HSCs and the associated ET-1
upregulation, we then investigated how the GW4064-treated
HSCs responded to the ET-1-induced contraction and compared
to that of untreated HSCs. HSC contraction was determined by
collagen gel contraction assay. Fig. 3 shows that GW4064-treated
HSCs were less active than DMSO-treated cells in response to ET-
1-induced contraction. This is likely due to the fact that GW4064-
treated cells are less transdifferentiated and are equipped with less
active contractile machinery/mechanism. To study if GW4064
has a similar inhibitory effect on fully activated HSCs, freshly
isolated HSCs were cultured for 7–10 days to allow full activation.
The cells were then treated with GW4064 or DMSO for 18 h
prior to ET-1-induced contraction. As shown in Fig. 4, transient
treatment with GW4064 also partially blocked the ET-1-mediated
contraction in fully activated HSCs. A similar result was obtained
with LX-1, a human HSC cell line (data not shown).
GW4064 treatment inhibited ET-1-mediated activation of
RhoA/Rho-kinase signaling
The above studies clearly showed that GW4064 exerted a
negative regulation of HSC contraction. To understand the
underlying mechanism, we investigated the effect of GW4064
treatment on RhoA/Rho-kinase signaling as this pathway plays an
important role in the contraction of activated HSCs. Initial study
with real time RT-PCR showed that there was no difference in the
mRNA expression levels of RhoA and its effector, Rho-kinase
between GW4064- and DMSO-treated cells (data not shown),
ruling out the possibility that FXR ligands affect HSC contraction
via regulating the expression levels of the components in the
RhoA/Rho-kinase signaling.
We then studied whether ET-1-induced activation of RhoA was
altered in HSCs following treatment with GW4064. RhoA
activities were determined by pull-down of GTP-RhoA. As shown
in Fig. 5, stimulation of activated rat HSCs with ET-1 induced a
significant increase in GTP-RhoA levels. Such activation of RhoA
was significantly inhibited by pretreatment of the cells with
GW4064 (Fig. 5).
To test if the reduced ET-1-stimulated RhoA activation in
GW4064-treated HSCs affects Rho-kinase activity, we studied the
phosphorylation of the Rho-kinase substrate moesin at Thr-558
with a site- and phosphor-specific antibody. As shown in Fig. 6,
ET-1 stimulation led to increased amounts of phosphorylated
moesin in activated rat HSCs. Again, the ET-1-induced
phosphorylation of moesin was significantly inhibited when the
cells were pretreated with GW4064.
One of the major consequences of activation of RhoA/Rho
kinase pathway is the phosphorylation of myosin light chains
(MLC), which is critically involved in the contraction of HSCs. To
further elucidate the mechanism by which GW4064 inhibits HSC
contraction, we studied if GW4064 affects the ET-1-induced
phosphorylation of MLC. As shown in Fig. 7, exposure of the
activated HSCs to ET-1 resulted in increased amounts of
phosphorylated MLC, which was significantly inhibited by
GW4064 pretreatment. The above results strongly suggest that
GW4064 negatively regulates the contractile response of HSCs to
ET-1 via inhibiting the RhoA/Rho kinase/MLC pathway.
Discussion
We have confirmed and expanded previous reports that
activation of FXR in HSCs inhibits their transdifferentiation.
We have also shown for the first time that FXR ligands exert
inhibitory effect on their contractile response to ET-1, a potent
vasoconstrictor.
It has been well established that activation of HSCs plays a key
role in the development of cirrhosis [1]. Activation of HSCs is
associated with altered and increased production of ECM that
contributes significantly to the fibrotic changes in the chronic liver
injury. Increasing evidence also suggests that activated HSCs gains
contractile function, which contributes to the intrahepatic
hemodynamic changes in cirrhosis [19]. HSCs reside in the
perisinusoidal space and extend elongate protrusions that run
along and encircle one or more sinusoids. Activated stellate cells
express a-smooth muscle actin, a marker of nonmuscle cell
contractility, in patients with different types of chronic liver injury.
A number of studies have demonstrated HSC contractile response
following stimulation by many different vasoactive mediators
including ET-1, arginine vasopressin, angiotensin II, thrombin,
eicosanoids, and a1-adrenergic agonists [4,5,6,20,21]. The best-
studied and most potent agonist for stellate cell contraction is ET-
1. ET-1 was originally identified as a potent vasoconstrictor
produced mainly by endothelial cells. During liver injury activated
stellate cells become a major source of ET-1. Stellate cells also
express endothelin receptors and ET-1 has a prominent contractile
effect on stellate cells and myofibroblasts, which may contribute to
portal hypertension in the cirrhotic liver. In addition, ET-1
promotes the proliferation of early-cultured stellate cells, whereas
it inhibits fully activated ones [22]. Thus, ET-1 exhibits an
autocrine effect on HSC and is involved in both HSC activation
and their contractile response.
A number of nuclear receptors have been reported to show
inhibitory effects on HSC activation. These include retinoid X
receptor, PPARs, pregnane-X-receptor, and FXR [7,8,9,23].
Treatment with the respective ligands has been shown to inhibit
the activation of the stellate cells and decrease the fibrotic changes
in animal models of liver injury. However little information is
available on the roles of nuclear receptors in the regulation of
stellate cell contraction.
As an initial step to address this question we studied the effect of
GW4064, a synthetic FXR ligand, on the expression of ET-1 and its
Figure 1. GW4064 treatment inhibited transdifferentiation of HSCs. Freshly isolated rat HSCs were cultured for 7 days in 10% FCS alone
(control) or 10% FCS medium containing 1 mmol/L GW4064. The expression of a-SMA mRNA (A) and protein (B) was examined by real-time RT-PCR
and immunofluorescence staining, respectively. Data are mean 6SE of 6 experiments. *P,.001 vs. control cells.
doi:10.1371/journal.pone.0013955.g001
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corresponding receptors on stellate cells. As shown in Fig. 2, there
was a significant increase in the mRNA expression level of ET-1
during the process of stellate cell activation. This upregulation in
ET-1 expression was significantly inhibited by GW4064 treatment.
We have previously shown that activation of FXR inhibited both
basal and LPS-stimulated ET-1 production in endothelial cells.
Functional promoter assays including electrophoretic mobility shift
assay (EMSA) and chromatin immunoprecipitation (ChIP) assay
Figure 2. GW4064 treatment inhibited the upregulation of ET-1 expression during HSC activation. Freshly isolated rat HSCs were
cultured for 7 days in 10% FCS alone (control) or 10% FCS medium containing 1 mmol/L GW4064. The mRNA expression levels of ET-1 (A), ETB (B) and
ETA (C) were examined by real-time RT-PCR, respectively. Data are mean 6SE of 6 experiments. *P,.001 vs. control cells.
doi:10.1371/journal.pone.0013955.g002
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suggest that FXR inhibits ET-1 expression via interference with NF-
kB/AP-1 signaling [24]. It is likely that FXR regulates ET-1
expression in stellate cells via a similar mechanism.
Despite the inhibitory effect on ET-1 expression, GW4064 showed
no effect on the expression of either ETA or ETB receptor in stellate
cells. A study by Chi and colleagues showed that retinoic acid exerted
an inhibitory effect on ETB expression in stellate cells but showed no
effect on either ET-1 or ETA expression [18]. Clearly, different nuclear
receptors regulate stellate cell activation via different mechanisms.
The freshly isolated stellate cells that were continuously treated
with GW4064 for 7 days showed reduced contractile response to
ET-1. This is unlikely due to changes in the expression levels of ET-1
receptors as shown in our RT-PCR studies. It is likely due to the fact
that GW4064-treated cells are less activated and are equipped with
Figure 3. GW4064 treatment of HSCs led to reduced contractile response to ET-1. Freshly isolated rat HSCs were cultured for 7 days in 10%
FCS medium alone (control) or 10% FCS medium containing 1 mmol/L GW4064. Collagen gel lattices that contained the control or GW4064-treated
HSCs were prepared as described in Materials & Methods. Hydrated collagen lattices were photographed 6 hours after addition of ET-1 (10 nM). Data
are mean 6SE of 6 experiments. *P,.001 vs. control cells.
doi:10.1371/journal.pone.0013955.g003
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less active contractile mechanism. It has been shown that a-SMA is
involved in the stellate cell contraction [25]. GW4064-treated cells
have significantly reduced levels of a-SMA expression compared to
fully activated stellate cells (Figure 1), which could account for, at
least partially, the reduced contractile response to ET-1.
After demonstrating a reduced contractile response in GW4064-
treated, partially activated stellate cells we further observed a similar
inhibitory effect of GW4064 in fully activated stellate cells. To
understand the underlying mechanism we focused on examining the
effect of GW4064 on RhoA/Rho kinase signaling as this pathway
plays a key role in stellate cell contraction [26]. Our preliminary study
with quantitative RT-PCR showed no effect of GW4064 on the
mRNA expression levels of either ETA or ETB. Thus it is unlikely
that GW4064 inhibits stellate cell contractile response to ET-1 via
modulating the expression of ET receptors at transcriptional level.
We then examined if GW6064 affects RhoA activation. Western
analysis clearly showed that the ET-1-mediated activation of RhoA,
measured as pull down of active GTP-RhoA, was significantly
inhibited by GW4064 treatment. So far, the mechanism responsible
for this inhibition is unclear. Preliminary studies showed that there
Figure 4. GW4064 treatment inhibited ET-1-induced contraction in fully activated HSCs. Rat HSCs were isolated and then cultured for 7 days
to allow full activation. Collagen gel lattices that contained fully activated HSCs were then prepared. They were treated with DMSO or 1 mmol/L GW4064 for
18 hours. Hydrated collagen lattices were photographed 6 hours after addition of ET-1 (10 nM). Data aremean6SE of 6 experiments. *P,.001 vs. control cells.
doi:10.1371/journal.pone.0013955.g004
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were no significant changes in the mRNA expression levels of the
receptors and several GTPase-activating proteins (p190 A-RhoGAP
and p190 B-RhoGAP) and guanine nucleotide exchange factors
(p115RhoGEF, PDZ-RhoGEF, and LARG) following treatment
with GW4064 (data not shown). It remains to be determined if
GW4064 treatment can induce any changes in the expression of
these molecules at protein level. Nonetheless, the impaired
activation of RhoA clearly resulted in a reduced activity of Rho-
kinase, as shown by reduced phosphorylation of moesin, a member
of the family of ezrin-radixin-moesin (ERM) proteins, which is
phosphorylated at Thr-558 by Rho-kinase.
The inhibition of RhoA/Rho kinase signaling is clearly
implicated in the GW4064-mediated inhibition of stellate cell
contraction as the phosphorylation of the downstream MLC is
significantly decreased. Many studies have shown that, similar to
smooth muscle cells, contraction of stellate cells is powered by
myosin II through its action on the actin cytoskeleton, a process
that is activated by phosphorylation of its myosin regulatory light
chain [27]. It’s likely that inhibition of ET-1-induced MLC
phosphorylation by GW4064 plays an important role in its
inhibitory effect on stellate cell contraction.
In summary, in addition to its known anti-fibrotic effect, our
study suggests a novel function of FXR in regulating intrahepatic
vascular resistance through its inhibitory effect on stellate cell
contraction. Although more studies are required to better
understand the underlying mechanism, inhibition of RhoA/Rho
kinase is likely to play a role in the FXR-mediated negative
regulation of stellate cell contraction.
Materials and Methods
Ethics Statement
All experimental manipulations and protocols in this study were
approved by the University of Pittsburgh Institutional Animal
Care and Use Committee. The animals were housed and
maintained in accordance with standards established in the
Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals (permit number: 0706848).
Animals and HSC isolation
Retired male Sprague-Dawley rats were used for primary HSC
isolation. HSCs were isolated via in situ proteinase/collagenase
perfusion followed by density gradient centrifugation as described
[28]. Primary cells were used at 5–7 days and were more than
95% pure. Cells were grown on standard tissue culture plastic
dishes in DMEM with 10% fetal bovine serum and antibiotics.
Quantitative real-time RT-PCR assay of gene expression
Total RNA was extracted from cells with TRIzol reagent
(Invitrogen) and the first-strand cDNA was synthesized by use of
SuperScript III reverse transcriptase (Invitrogen). Real-time PCR
analysis of rat genes was performed by use of SYBR Green-based
assays with the ABI 7300 Real-Time PCR System (Applied
Biosystems, Foster City, CA) [29]. Each amplification mixture
(25 ml) contains 25 ng of cDNA, 1.25 ml of primers and FAM-labeled
florigenic probe, and 12.5 ml of Universal PCR Master mix.
Amplification was performed under the following conditions: 50uC
for 2 min, 95uC for 10 min, and 40 cycles of 95uC for 15 s, and 60uC
for 1 min. Transcript abundance, normalized to b-glucuronidase
expression, was expressed as fold increase over a calibrated sample.
Immunostaining of cultured rat HSCs
Immunodetection of actin2 was performed following our
published protocol [24]. Briefly, the cells that were grown on
glass cover slips were washed three times with phosphate-buffered
saline (PBS) and fixed with 4% (w/v) paraformaldehyde in PBS for
15 minutes at room temperature. After fixation, cells were rinsed
with PBS and then permeabilized with 0.1% (v/v) Triton X-100,
0.1% (w/v) sodium citrate for 2 minutes on ice. Unspecific binding
sites were blocked with 10% (v/v) goat serum in PBS, 0.1% (w/v)
Figure 5. GW4064 treatment inhibited ET-1-induced RhoA activation in activated HSCs. Activated HSCs were treated with DMSO or
1 mmol/L GW4064 for 18 hours. ET-1 (10 nM) was then added to the medium, and the cells were harvested 10 min later. RhoA-GTP pull-down assay
was performed using RhoA-GTP assay kit. RhoA-GTP pull-down and total RhoA fractions were probed by Western blot with anti-RhoA antibody. Blots
are representative of experiments performed three times with similar results.
doi:10.1371/journal.pone.0013955.g005
Figure 6. GW4064 treatment inhibited ET-1-induced Rho-kinase activity in activated HSCs. Activated HSCs were treated with DMSO or
1 mmol/L GW4064 for 18 hours. ET-1 (10 nM) was then added to the medium, and the cells were harvested 10 min later. Phosphorylation of meosin
was detected by Western using appropriate phospho-specific antibody. An immunoblot of total meosin present in the cell extracts is shown as a
loading control (lower panel). A representative immunoblot from three independent experiments is presented.
doi:10.1371/journal.pone.0013955.g006
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bovine serum albumin (BSA). Cells were then incubated for
2 hours at room temperature with rabbit anti-rat actin2 (Santa
Cruz Biotechnology, Santa Cruz, CA) for 1 h, followed by labeling
with Alexa 488-conjugated goat anti-rabbit IgG (Molecular
Probes, Eugene, OR) for 1 h. Cells were observed under a
confocal microscope.
Western blot analysis for moesin and MLC protein
expression
Protein extraction and Western blot analysis were performed as
described previously [30]. Goat anti-moesin and anti-p-moesin
antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Rabbit anti-MLC and p-MLC antibodies were
purchased from Cell Signaling Technology, Inc. (Danvers, MA).
Horseradish peroxidase-labeled donkey anti-goat, goat anti-rabbit
and the electrochemiluminescence kit were purchased from GE
Healthcare (Piscataway, NJ).
Pull-down assays for active RhoA
Cells were treated with and without ET-1 (10 nM) for 10 min for
all experiments in which RhoA was assayed. To the diluted buffer
(Upstate, Temecula, CA) in water, 10 mg/mL of aprotinin and
10 mg/mL leupeptin from Roche Molecular Biochemicals (Chi-
cago, IL) were added. Cells were rinsed twice with PBS, and lysis
buffer was added. Rho reagent slurry (Upstate) was added, samples
were incubated, and beads were pelleted via brief centrifugation.
Beads were resuspended in Laemmli-reducing buffer from Invitro-
gen (Carlsbad, CA) and boiled for 5 minutes. Supernatant and
agarose pellets were mixed, and samples were loaded on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gel (Invitrogen)
and blotted to a nitrocellulose membrane. Anti-Rho antibody and
mouse monoclonal IgG1 (Upstate) were applied for overnight, and
appropriate secondary antibody was used for 1 hour. Chemoilu-
minescent from Pierce (Rockford, IL) was applied to the membrane
for 5 minutes and developed on radiographic film.
Gel contraction assay
Contractility of HSCs was evaluated using collagen gel lattices
on 24-well culture plates as described [31]. Wells were filled with
PBS containing 1% bovine serum albumin for 1 hour at 37uC,
washed twice with PBS, and air-dried. Type1 rat-tail collagen
(3.69 mg/mL; BD Bioscience, Bedford, MA) was adjusted
according to the manufacturer’s instructions. The final collagen
concentration was 2 mg/mL. The collagen solution was poured
and incubated for 1 hour at 37uC to allow gelation. HSCs were
isolated and cultured as described. After 7 days of culture, cells
were trypsinized, suspended (2.56105 cells/mL) in DMEM
supplemented with 10% fetal bovine serum and antibiotics, and
plated on the collagen gels (2 mL cell suspension/well). After
incubation overnight to allow cell attachment, serum-free
conditions were introduced for 4 hours and the cells were washed
three times with serum-free DMEM. Gels were detached from the
plates. HSCs were treated with GW4064 for 18 hour. ET-1
(10 nM) was then added to the culture media just before the
lattices were detached. Buffer without ET-1 was used as a control.
The gels were photographed every hour for 6 hours. Surface area
of the collagen gels was measured using digital image analysis
software. All experiments were performed as triplicate.
Statistical analysis
All data are expressed as means 6 S.E.M. unless otherwise
stated. Comparisons between two groups were made with
unpaired Student’s t test. Comparisons between three or more
groups were made with analysis of variance followed by Tukey-
Kramer post hoc analysis. In all cases, P,0.05 was considered
statistically significant.
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